SCHEMBL4552685

SCHEMBL4552685

CCCCCCC(CC(C)=O)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 2/20 0.50
CA2 P00918 2/20 0.46
ZDHHC7 Q9NXF8 1/20 0.43
GPR84 Q9NQS5 7/20 0.42
CA1 P00915 1/20 0.42
FAAH O00519 1/20 0.41
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
FFAR1 O14842 1/20 0.40
BIRC2 Q13490 1/20 0.39
CES2 O00748 1/20 0.39
MAPT P10636 1/20 0.39
LCK P06239 1/20 0.39
PPARD Q03181 1/20 0.39
ZDHHC20 Q5W0Z9 1/20 0.39
ZDHHC2 Q9UIJ5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240433 1.00 CPB2 (0.50) CPB2CA2ZDHHC7GPR84CA1
Oxalic Acid SCHEMBL10673743 0.95 CPB2 (0.46) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL12577919 0.93 CA2 (0.48) CPB2CA2CA1BIRC2
SCHEMBL18531126 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL19148651 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL23879492 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL5580131 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL571313 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL25341592 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL5516547 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3098230-B1 THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. BONAC CORP (JP) 2020-05-06 EP disclosed
US-9988415-B2 Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid BONAC CORPORATION (JP) 2018-06-05 US disclosed
EP-2749565-B1 NUCLEOSIDE PHOSPHORAMIDATES FOR PRODUCING NUCLEIC ACIDS BONAC CORP (JP) 2017-05-31 EP disclosed
EP-3098230-A1 THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. Bonac Corporation (JP) 2016-11-30 EP disclosed
EP-3089769-A1 DRUG ELUTING BALLOON WITH PREFERRED DRUG ORIENTATION TO IMPROVE DRUG TRANSFER EFFICIENCY Boston Scientific Scimed, Inc. (US) 2016-11-09 EP disclosed
US-9481702-B2 Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid BONAC CORPORATION (JP) 2016-11-01 US disclosed
US-20160176810-A1 GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID BONAC CORPORATION (JP) 2016-06-23 US disclosed
US-9359360-B2 TLR agonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-06-07 US disclosed
EP-1931352-B1 TLR AGONISTS UNIV CALIFORNIA (US) 2016-04-13 EP disclosed
EP-2510946-B1 Conjugates of synthetic tlr agonists and uses therefor UNIV CALIFORNIA (US) 2015-08-05 EP disclosed
US-5580985-A ANTIARTHRITIC AGENT; SIDE EFFECT REDUCTION G. D. SEARLE & CO. (US) 1996-12-03 US disclosed
US-5486534-A 3,4-substituted pyrazoles for the treatment of inflammation G. D. SEARLE & CO. (US) 1996-01-23 US disclosed
US-5124478-A ACID-LABILE ANCHOR GROUPS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY A SOLID-PHASE METHOD HOECHST AKTIENGESELLSCHAFT (DE) 1992-06-23 US disclosed
EP-0284359-B1 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1992-01-08 EP disclosed
US-4997836-A Inhibitor of platelet activating factor TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-03-05 US disclosed
EP-0368670-A1 Trisubstituted piperazine compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1990-05-16 EP disclosed
US-4880809-A HYPOTENSIVE AGENTS, AMIDE DERIVATIVES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-11-14 US disclosed
EP-0284359-A1 1,4-Disubstituted piperazine compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1988-09-28 EP disclosed
US-4735651-A HERBICIDES; ROOT INHIBITION THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1988-04-05 US disclosed
US-4432972-A HYPOTENSIVE AGENTS, KANALGESICS, AND ANGIOTENSIN AND ENKEPHALIN INHIBITION E. R. SQUIBB & SONS, INC. (US) 1984-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176810-A1 GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID DDOST, TENT4A, TRDMT1 CPB2 2410/4885CA2 942/4885ZDHHC7 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.